InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (0 ops.)
Browse the full record of transactions filed by Hollander David, Directeur de la R&D. Director active across 1 company, notably Aerie Pharmaceuticals INC. Aggregated, 4 filings have been published. Activity tracked since 11 November 2021. The latest transaction was disclosed on 4 February 2022 (Retenue fiscale). Regulator: SEC (Form 4). The full history is free.
Declarations4 total
927 shares@ US$7.0510.1% of flowCommon StockSEC:0001209191-22-007902:0
927 shares@ US$7.0520.1% of flowCommon StockSEC:0001209191-22-007902
2,162 shares@ US$12.0639.9% of flowCommon StockSEC:0001209191-21-064473:0
2,162 shares@ US$12.0679.9% of flowCommon StockSEC:0001209191-21-064473
4 of 4 declarations
About Hollander David
David Hollander is the Chief R&D Officer at Aerie Pharmaceuticals Inc. He oversees the research and development activities of the company, which specializes in the pharmaceutical sector. His role is essential for innovation and the development of new products at Aerie.
